

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Oludare Odumosu
Date of last notice	17 January 2025

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	4 December 2025
No. of securities held prior to change	A. 131,766 ordinary shares B. 40,000 - unlisted options expiring 24/11/2027 @ \$2.00 C. 40,000 - unlisted options expiring 24/11/2027 @ \$4.00 D. 40,000 - unlisted options expiring 24/11/2027 @ \$6.00 E. 40,000 - unlisted options expiring 24/11/2027 @ \$8.00 F. 40,000 - unlisted options expiring 24/11/2027 @ \$10.00
Class	G. Convertible Note
Number acquired	386,847
Number disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	USD100,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	A. 131,766 ordinary shares B. 40,000 - unlisted options expiring 24/11/2027 @ \$2.00 C. 40,000 - unlisted options expiring 24/11/2027 @ \$4.00 D. 40,000 - unlisted options expiring 24/11/2027 @ \$6.00 E. 40,000 - unlisted options expiring 24/11/2027 @ \$8.00 F. 40,000 - unlisted options expiring 24/11/2027 @ \$10.00 G. 386,847 convertible notes
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Convertible notes to replace Convertible Loan Agreement approved by shareholders 19 November 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	ZELIRA THERAPEUTICS LIMITED
ABN	27 103 782 378

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr. Donna Gentile O'Donnel
Date of last notice	24 November 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	4 December 2025
No. of securities held prior to change	A. 10,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 10,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 10,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 10,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 10,000 - unlisted options expiring 24/11/2027 @ \$10.00 F. 95,000 - unlisted options expiring 24/11/2026 @ \$1.15
Class	G. Convertible Note
Number acquired	193,423
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	USD50,000

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

No. of securities held after change	A. 10,000 - unlisted options expiring 24/11/2027 @ \$2.00 B. 10,000 - unlisted options expiring 24/11/2027 @ \$4.00 C. 10,000 - unlisted options expiring 24/11/2027 @ \$6.00 D. 10,000 - unlisted options expiring 24/11/2027 @ \$8.00 E. 10,000 - unlisted options expiring 24/11/2027 @ \$10.00 F. 95,000 - unlisted options expiring 24/11/2026 @ \$1.15 G. 193,423 Convertible Note
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Issue of Convertible notes to replace Convertible Loan Agreement approved by shareholders 19 November 2025.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	N/A
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

⁺ See chapter 19 for defined terms.